Natasha Frontera

Ms. Natasha Frontera


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2024 in Cancers
Verified
Journal Article
Open access
PDF file
MVMiguel Mayol Del Valle
Miguel Mayol Del Valle
BMBryan Morales
Bryan Morales
BPBrandon Philbrick
Brandon Philbrick
SASegun Adeagbo
Segun Adeagbo
SGSubir Goyal
Subir Goyal
KHKimberly B. Bojanowski Hoang
Kimberly B. Bojanowski Hoang
Intramedullary spinal cord tumors (IMSCTs) harbor unique genetic mutations which may play a role in prognostication and management. To this end, we present the largest cohort of IMSCTs with genetic characterization in the literature from our multi-site institutional registry. A total of 93 IMSCT patient records were reviewed from the years 1999 to 2020. Out of these, 61 complied with all inclusion criteria, 14 of these patients had undergone genetic studies with 8 undergoing whole-genomic sequencing. Univariate analyses were used to assess any factors associated with progression-free survival (PFS) using the Cox proportional hazards model. Firth’s penalized likelihood approach was used to account for the low event rates. Fisher’s exact test was performed to compare whole-genome analyses and specific gene mutations with progression. PFS (months) was given as a hazard ratio. Only the absence of copy neutral loss of heterozygosity (LOH) was shown to be significant (0.05, p = 0.008). Additionally, higher risk of recurrence/progression was associated with LOH (p = 0.0179). Our results suggest LOH as a genetic predictor of shorter progression-free survival, particularly within ependymoma and glioblastoma tumor types. Further genomic research with larger multi-institutional datasets should focus on these mutations as possible prognostic factors.

13 July 2023 in Journal of Neurological Surgery Reports
Verified
Journal Article
Open access
PDF file
NFNatasha Frontera
Natasha Frontera
JRJulio Rosado-Philippi
Julio Rosado-Philippi
FDFrancisco Del Valle Díaz
Francisco Del Valle Díaz
ADAlejandra Santiago Díaz
Alejandra Santiago Díaz
AMAdriana Vázquez Medina
Adriana Vázquez Medina
MVMiguel Mayol del Valle
Miguel Mayol del Valle
The aim of this report is to describe TransOrbital NeuroEndoscopic Surgery (TONES) as a safe alternative for obtaining a cavernous sinus (CS) biopsy. We describe this technique in a patient with a diffuse large B cell lymphoma mimicking Tolosa–Hunt's syndrome. Articles were gathered querying PubMed, Embase, and Scopus databases with terms related to a “transorbital neuroendoscopic approach.” The literature search was performed by two independent authors (N.L.F. and J.R.), with inconsistencies resolved by the senior author (M.M.D.V.). After screening abstracts for relevance, full-length articles were reviewed for pertinent variables. A comparison was conducted with the illustrative case of a 69-year-old woman who presented to the emergency department with vertigo, ophthalmoplegia, and diplopia for 2 months. A brain magnetic resonance imaging revealed an infiltrative lesion at the left CS. A presumptive diagnosis of Tolosa–Hunt syndrome was made, but a confirmatory biopsy was performed using TONES. Based on our cadaveric study, literature review, and case report, the TONES approach was safe, effective for tissue diagnosis, and associated with minor morbidity and reduced hospital stay. Additional prospective studies are required to study its viability and safety in a larger group of patients.

16 December 2025 in Epidemiologia
Verified
Journal Article
Open access
PDF file
EPEric J Pérez-Pérez
Eric J Pérez-Pérez
EREsteban Ruben Rivera-Rivera
Esteban Ruben Rivera-Rivera
NFNatasha Frontera
Natasha Frontera
ACAlejandro Cedeño-Moran
Alejandro Cedeño-Moran
CCCamelia Carvajal-Matta
Camelia Carvajal-Matta
MVMiguel Mayol Del Valle
Miguel Mayol Del Valle
Objectives: Neural tube defects such as myelomeningocele (MMC) remain a significant public health concern despite prevention efforts. Public health measures have reduced the global MMC incidence, but socioeconomic disparities may limit their impact. Puerto Rico (PR) is a United States (US) territory; however, its socioeconomic landscape is vastly different, which may contribute to differences in MMC incidence. In this study, we aimed to compare the differences in MMC incidence and annual variability between PR and the US. Materials and Methods: Data on MMC incidence for the US was obtained from the Centers for Disease Control’s National Vital Statistics Reports, and data for PR from the Puerto Rico Birth Defects Surveillance and Prevention System. Annual percentage change (APC) was used to evaluate year-to-year variation, and multiple linear regression analysis was applied to compare incidence rates. Results: The mean annual MMC incidence in 1996–2020 was 4.88 per 10,000 live births in PR (SD = 1.86), and 1.78 (SD = 0.35) in the US, with an estimated mean difference of 3.11 (p < 0.001). APCs during this period varied significantly, ranging from +200% to −63%. A subgroup analysis after folic acid fortification efforts in PR (1999–2020) showed a persistently elevated incidence in PR (mean = 4.41, SD = 1.33) vs. US (mean = 1.67, SD = 0.25), with an estimated mean difference of 2.72 (p < 0.001). Conclusions: Despite folic acid fortification and public health interventions, MMC incidence in PR remains higher and more variable. These findings underscore the need for improved disease reporting and targeted, region-specific preventive strategies.